Rentschler Biopharma, a global CDMO for biopharmaceuticals, has officially inaugurated its novel production line in Milford, Massachusetts, US — which is now fully operational.
The company reports that it also has a major project underway that involves the new line, as well as several additional schemes in the pipeline.
Facility expansion enhances US biomanufacturing capabilities
The line is a huge investment for the company, with a 22,000 sqft area dedicated to manufacturing and cleanroom space that contains four new 2,000L single-use bioreactors — meaning the site now has three production lines.
The multi-product facility doubles Rentschler Biopharma's global cGMP capacity, and the first engineering run of a 2,000L batch has already proven successful.
Tom Roberts, President of Rentschler Biopharma and General Manager US, noted: “Our new line is vital to growing our business and effectively serving the US market, and I am excited about bringing in new clients as well as expanding our support of existing ones with a reliability they can trust."
"We are embarking on a new stage in our long and successful history and are poised to tackle the most complex challenges in biopharmaceutical development and manufacturing. In light of evolving industry legislation, we remain committed to supporting our clients responsibly and contributing positively to both national interests and global health advancements.”
Since Rentschler Biopharma acquired the Milford site in 2019, the company has expanded it from 93,000 to 138,000 sqft — creating a significant number of jobs for the local community.
[Photo credit: Rentschler Biopharma]
